Compare Gilead Sciences, Inc. (GILD) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Gilead Sciences, Inc. trades at $136 (market cap $163.51B), while State Street Real Estate Select Sector SPDR ETF trades at $45.48. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while State Street Real Estate Select Sector SPDR ETF pays none, and State Street Real Estate Select Sector SPDR ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | XLRE | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $45.36 |
52-Week Low | $108.22 | $40.01 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
XLRE, the Real Estate Select Sector SPDR ETF, trades at $45.25, up 1.72% today, with a bullish technical signal from moving averages and neutral oscillators. The fund, with $7.71 billion in assets, offers a low 0.08% expense ratio and a trailing distribution yield of 3.4%. Recent news highlights REITs' resilience amid interest rate volatility and a quiet market revival, with the sector gaining 11% year-to-date as of late May 2026.
The outlook for XLRE is cautiously optimistic, supported by solid REIT fundamentals, including steady same-store NOI growth and potential as a geopolitical hedge. Risks include sensitivity to rising Treasury yields and inflation, which could pressure dividends. Analyst sentiment is mixed, focusing on the ETF's cost efficiency versus global alternatives, with the sector showing recovery signs but facing macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
